Antiviral drug resistance of human cytomegalovirus

Clinical Microbiology Reviews

Volumn 23, Issue 4, 2010, Pages 689-712

  Lurain, Nell S ^a   Chou, Sunwen ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; ARTESUNATE; BENZIMIDAVIR; CIDOFOVIR; DNA POLYMERASE; EVEROLIMUS; FOSCARNET; GANCICLOVIR; LEFLUNOMIDE; RAPAMYCIN; VALGANCICLOVIR;

ANTIVIRAL THERAPY; CLINICAL ASSESSMENT; COSMID; CYTOMEGALOVIRUS INFECTION; DNA MODIFICATION; DNA POLYMORPHISM; DNA SEQUENCE; DRUG INDICATION; GENE MUTATION; GENE REPLICATION; GENE STRUCTURE; GENE TARGETING; GENETIC RECOMBINATION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CYTOMEGALOVIRUS; LABORATORY DIAGNOSIS; MOLECULAR CLONING; NONHUMAN; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; VIRUS GENOME; VIRUS MORPHOLOGY; VIRUS MUTATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOSINE; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; FOSCARNET; GANCICLOVIR; GENOME, VIRAL; HUMANS; PHOSPHONIC ACIDS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SEQUENCE ANALYSIS, DNA;

HUMAN HERPESVIRUS 5; MUSHROOM BACILLIFORM VIRUS;

EID: 78049355534     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00009-10     Document Type: Review

References (132)

1. Abraham, B., S. Lastere, J. Reynes, F. Bibollet-Ruche, N. Vidal, and M. Segondy. 1999. Ganciclovir resistance and UL97 gene mutations in cyto-megalovirus blood isolates from patients with AIDS treated with ganciclovir. J. Clin. Virol. 13:141-148.
2. Amir, J., D. G. Wolf, and I. Levy. Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir. Eur. J. Pediatr., in press.
3. Anders, D. G., and W. Gibson. 1988. Location, transcript analysis, and partial nucleotide sequence of the cytomegalovirus gene encoding an early DNA-binding protein with similarities to ICP8 of herpes simplex virus type 1. J. Virol. 62:1364-1372.
4. Avery, R. K., B. J. Bolwell, B. Yen-Lieberman, N. Lurain, W. J. Waldman, D. L. Longworth, A. J. Taege, S. B. Mossad, D. Kohn, J. R. Long, J. Curtis, M. Kalaycio, B. Pohlman, and J. W. Williams. 2004. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant. 34:1071-1075.
5. Avery, R. K., F. M. Marty, L. Strasfeld, I. Lee, A. Arrieta, C. S., and S. Villano. 2009. Oral maribavir for treatment of resistant or refractory cytomegalovirus infections in transplant recipients, abstr. V-1256. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
6. Baek, M. C., P. M. Krosky, and D. M. Coen. 2002. Relationship between autophosphorylation and phosphorylation of exogenous substrates by the human cytomegalovirus UL97 protein kinase. J. Virol. 76:11943-11952.
7. Baldanti, F., D. Michel, L. Simoncini, M. Heuschmid, A. Zimmermann, R. Minisini, P. Schaarschmidt, T. Schmid, G. Gerna, and T. Mertens. 2002. Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system. Antiviral Res. 54:59-67. (Pubitemid 34219175)
8. Baldanti, F., S. Paolucci, A. Parisi, L. Meroni, and G. Gerna. 2002. Emergence of multiple drug-resistant human cytomegalovirus variants in 2 patients with human immunodeficiency virus infection unresponsive to highly active antiretroviral therapy. Clin. Infect. Dis. 34:1146-1149.
9. Baldanti, F., E. Silini, A. Sarasini, C. L. Talarico, S. C. Stanat, K. K. Biron, M. Furione, F. Bono, G. Palu, and G. Gerna. 1995. A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. J. Virol. 69:796-800.
10. Baldanti, F., M. R. Underwood, S. C. Stanat, K. K. Biron, S. Chou, A. Sarasini, E. Silini, and G. Gerna. 1996. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J. Virol. 70:1390-1395.
11. Baldanti, F., M. R. Underwood, C. L. Talarico, L. Simoncini, A. Sarasini, K. K. Biron, and G. Gerna. 1998. The Cys607→Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients. Antimicrob. Agents Chemother. 42:444-446.
12. Bate, S. L., S. C. Dollard, and M. J. Cannon. 2010. Cytomegalovirus sero-prevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin. Infect. Dis. 50:1439-1447.
13. Battiwalla, M., P. Paplham, N. G. Almyroudis, A. McCarthy, A. Abdelhalim, A. Elefante, P. Smith, J. Becker, P. L. McCarthy, and B. H. Segal. 2007. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. Transpl. Infect. Dis. 9:28-32.
14. Biron, K. K., J. A. Fyfe, S. C. Stanat, L. K. Leslie, J. B. Sorrell, C. U. Lambe, and D. M. Coen. 1986. A human cytomegalovirus mutant resistant to the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc. Natl. Acad. Sci. U. S. A. 83:8769-8773.
15. Biron, K. K., R. J. Harvey, S. C. Chamberlain, S. S. Good, A. A. Smith III, M. G. Davis, C. L. Talarico, W. H. Miller, R. Ferris, R. E. Dornsife, S. C. Stanat, J. C. Drach, L. B. Townsend, and G. W. Koszalka. 2002. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46:2365-2372.
16. Blanco, L., A. Bernad, M. A. Blasco, and M. Salas. 1991. A general structure for DNA-dependent DNA polymerases. Gene 100:27-38.
17. Boeckh, M., and P. Ljungman. 2009. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113:5711-5719.
18. Bogner, E. 2002. Human cytomegalovirus terminase as a target for antiviral chemotherapy. Rev. Med. Virol. 12:115-127.
19. Boivin, G., S. Chou, M. R. Quirk, A. Erice, and M. C. Jordan. 1996. Detection of ganciclovir resistance mutations quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease. J. Infect. Dis. 173:523-528.
20. Boivin, G., C. Gilbert, A. Gaudreau, I. Greenfield, R. Sudlow, and N. A. Roberts. 2001. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J. Infect. Dis. 184:1598-1602.
21. Boivin, G., N. Goyette, C. Gilbert, and E. Covington. 2005. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J. Med. Virol. 77:425-429.
22. Boivin, G., N. Goyette, C. Gilbert, A. Humar, and E. Covington. 2005. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl. Infect. Dis. 7:166-170.
23. Boivin, G., N. Goyette, C. Gilbert, N. Roberts, K. Macey, C. Paya, M. D. Pescovitz, A. Humar, E. Dominguez, K. Washburn, E. Blumberg, B. Alexander, R. Freeman, N. Heaton, and E. Covington. 2004. Absence of cytomegalovirus- resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J. Infect. Dis. 189:1615-1618.
24. Boivin, G., N. Goyette, H. Rollag, A. G. Jardine, M. D. Pescovitz, A. Asberg, J. Ives, A. Hartmann, and A. Humar. 2009. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir. Ther. 14:697-704.
25. Borst, E. M., G. Hahn, U. H. Koszinowski, and M. Messerle. 1999. Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J. Virol. 73:8320-8329.
26. Bourgeois, C., N. Sixt, J. B. Bour, and P. Pothier. 1997. Value of a ligase chain reaction assay for detection of ganciclovir resistance-related mutation 594 in UL97 gene of human cytomegalovirus. J. Virol. Methods 67:167-175. (Pubitemid 27373703)
27. Boutolleau, D., C. Deback, C. Bressollette-Bodin, F. Conan, Z. Ait-Arkoub, B. M. Imbert-Marcille, and H. Agut. 2009. Genetic analysis and putative role in resistance to antivirals of the human cytomegalovirus DNA polymerase UL44 processivity factor. Antivir. Ther. 14:847-852.
28. Boutolleau, D., C. Deback, C. Bressollette-Bodin, S. Varnous, N. Dhedin, B. Barrou, J. P. Vernant, I. Gandjbakhch, B. M. Imbert-Marcille, and H. Agut. 2009. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection. Antiviral Res. 81:174-179.
29. Bowen, E. F., J. M. Cherrington, P. D. Lamy, P. D. Griffiths, M. A. Johnson, and V. C. Emery. 1999. Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy. J. Med. Virol. 58:402-407.
30. Bradley, A. J., N. S. Lurain, P. Ghazal, U. Trivedi, C. Cunningham, K. Baluchova, D. Gatherer, G. W. Wilkinson, D. J. Dargan, and A. J. Davison. 2009. High-throughput sequence analysis of variants of human cytomegalovirus strains Towne and AD169. J. Gen. Virol. 90:2375-2380.
31. Braithwaite, D. K., and J. Ito. 1993. Compilation, alignment, and phylogenetic relationships of DNA polymerases. Nucleic Acids Res. 21:787-802.
32. Buerger, I., J. Reefschlaeger, W. Bender, P. Eckenberg, A. Popp, O. Weber, S. Graeper, H. D. Klenk, H. Ruebsamen-Waigmann, and S. Hallenberger. 2001. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J. Virol. 75:9077-9086. (Pubitemid 32851912)
33. Cha, T. A., E. Tom, G. W. Kemble, G. M. Duke, E. S. Mocarski, and R. R. Spaete. 1996. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J. Virol. 70:78-83.
34. Chee, M. S., G. L. Lawrence, and B. G. Barrell. 1989. Alpha-, beta- and gammaherpesviruses encode a putative phosphotransferase. J. Gen. Virol. 70:1151-1160.
35. Cheeran, M. C., J. R. Lokensgard, and M. R. Schleiss. 2009. Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. Clin. Microbiol. Rev. 22:99-126.
36. Cherrington, J. M., M. D. Fuller, P. D. Lamy, R. Miner, J. P. Lalezari, S. Nuessle, and W. L. Drew. 1998. In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome. J. Infect. Dis. 178:1821-1825.
37. Chevillotte, M., J. von Einem, B. M. Meier, F. M. Lin, H. A. Kestler, and T. Mertens. 2009. A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes. Antiviral Res. 85:318-327.
38. Chou, S. 1999. Antiviral drug resistance in human cytomegalovirus. Transpl. Infect. Dis. 1:105-114.
39. Chou, S. 2008. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev. Med. Virol. 18:233-246.
40. Chou, S. 2009. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. Antimicrob. Agents Chemother. 53:81-85.
41. Chou, S. 2010. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob. Agents Chemother. 54:2371-2378.
42. Chou, S., A. Erice, M. C. Jordan, G. M. Vercellotti, K. R. Michels, C. L. Talarico, S. C. Stanat, and K. K. Biron. 1995. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis. 171:576-583.
43. Chou, S., S. Guentzel, K. R. Michels, R. C. Miner, and W. L. Drew. 1995. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J. Infect. Dis. 172:239-242.
44. Chou, S., N. S. Lurain, K. D. Thompson, R. C. Miner, and W. L. Drew. 2003. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 188:32-39.
45. Chou, S., N. S. Lurain, A. Weinberg, G. Y. Cai, P. L. Sharma, and C. S. Crumpacker. 1999. Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. Antimicrob. Agents Chemother. 43:1500-1502.
46. Chou, S., G. Marousek, S. Guentzel, S. E. Follansbee, M. E. Poscher, J. P. Lalezari, R. C. Miner, and W. L. Drew. 1997. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J. Infect. Dis. 176:786-789.
47. Chou, S., G. Marousek, S. Li, and A. Weinberg. 2008. Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. J. Clin. Virol. 43:107-109.
48. Chou, S., G. Marousek, D. M. Parenti, S. M. Gordon, A. G. LaVoy, J. G. Ross, R. C. Miner, and W. L. Drew. 1998. Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. J. Infect. Dis. 178:526-530.
49. Chou, S., and G. I. Marousek. 2008. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. J. Virol. 82:246-253.
50. Chou, S., G. I. Marousek, A. E. Senters, M. G. Davis, and K. K. Biron. 2004. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J. Virol. 78:7124-7130.
51. Chou, S., G. I. Marousek, L. C. Van Wechel, S. Li, and A. Weinberg. 2007. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob. Agents Chemother. 51:4160-4162.
52. Chou, S., and C. L. Meichsner. 2000. A nine-codon deletion mutation in the cytomegalovirus UL97 phosphotransferase gene confers resistance to ganciclovir. Antimicrob. Agents Chemother. 44:183-185.
53. Chou, S., R. C. Miner, and W. L. Drew. 2000. A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. J. Infect. Dis. 182:1765-1768.
54. Chou, S., L. C. Van Wechel, H. M. Lichy, and G. I. Marousek. 2005. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob. Agents Chemother. 49:2710-2715.
55. Chou, S., L. C. Van Wechel, and G. I. Marousek. 2006. Effect of cell culture conditions on the anticytomegalovirus activity of maribavir. Antimicrob. Agents Chemother. 50:2557-2559.
56. Chou, S., R. H. Waldemer, A. E. Senters, K. S. Michels, G. W. Kemble, R. C. Miner, and W. L. Drew. 2002. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J. Infect. Dis. 185:162-169.
57. Chou, S., L. C. Wechel, and G. I. Marousek. 2007. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J. Infect. Dis. 196:91-94.
58. Chrisp, P., and S. P. Clissold. 1991. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41:104-129.
59. Cihlar, T., M. D. Fuller, and J. M. Cherrington. 1998. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J. Virol. 72:5927-5936.
60. Cihlar, T., M. D. Fuller, A. S. Mulato, and J. M. Cherrington. 1998. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology 248:382-393.
61. Crumpacker, C. S. 1996. Ganciclovir. N. Engl. J. Med. 335:721-729.
62. Dankner, W. M., D. Scholl, S. C. Stanat, M. Martin, R. L. Sonke, and S. A. Spector. 1990. Rapid antiviral DNA-DNA hybridization assay for human cytomegalovirus. J. Virol. Methods 28:293-298.
63. De Clercq, E. 2003. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin. Microbiol. Rev. 16:569-596.
64. Demopoulos, L., M. Polinsky, G. Steele, D. Mines, M. Blum, M. Caulfield, A. Adamkovic, Q. Liu, M. B. Harler, C. Hahn, and A. Singh. 2008. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. Transplant. Proc. 40: 1407-1410.
65. Dolan, A., C. Cunningham, R. D. Hector, A. F. Hassan-Walker, L. Lee, C. Addison, D. J. Dargan, D. J. McGeoch, D. Gatherer, V. C. Emery, P. D. Griffiths, C. Sinzger, B. P. McSharry, G. W. Wilkinson, and A. J. Davison. 2004. Genetic content of wild-type human cytomegalovirus. J. Gen. Virol. 85:1301-1312.
66. Drew, W. L., R. Anderson, W. Lang, R. C. Miner, G. Davis, and J. Lalezari. 1995. Failure of high-dose oral acyclovir to suppress CMV viruria or induce ganciclovir-resistant CMV in HIV antibody positive patients. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8:289-291.
67. Ducancelle, A., S. Alain, F. Petit, M. J. Sanson Le Pors, and M. C. Mazeron. 2007. Development and validation of a non-radioactive DNA polymerase assay for studying cytomegalovirus resistance to foscarnet. J. Virol. Methods 141:212-215.
68. Ducancelle, A., G. Champier, S. Alain, F. Petit, M. J. Le Pors, and M. C. Mazeron. 2006. A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. Antivir. Ther. 11:537-540.
69. Eckle, T., P. Lang, L. Prix, G. Jahn, T. Klingebiel, R. Handgretinger, B. Selle, D. Niethammer, and K. Hamprecht. 2002. Rapid development of ganciclovir-resistant cytomegalovirus infection in children after allogeneic stem cell transplantation in the early phase of immune cell recovery. Bone Marrow Transplant. 30:433-439. (Pubitemid 35256415)
70. Efferth, T., M. R. Romero, D. G. Wolf, T. Stamminger, J. J. Marin, and M. Marschall. 2008. The antiviral activities of artemisinin and artesunate. Clin. Infect. Dis. 47:804-811.
71. Emery, V. C., A. V. Cope, E. F. Bowen, D. Gor, and P. D. Griffiths. 1999. The dynamics of human cytomegalovirus replication in vivo. J. Exp. Med. 190: 177-182.
72. Emery, V. C., and A. F. Hassan-Walker. 2002. Focus on new drugs in development against human cytomegalovirus. Drugs 62:1853-1858.
73. Erice, A., S. Chou, K. K. Biron, S. C. Stanat, H. H. Balfour, Jr., and M. C. Jordan. 1989. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N. Engl. J. Med. 320:289-293.
74. Erice, A., C. Gil-Roda, J. L. Perez, H. H. Balfour, Jr., K. J. Sannerud, M. N. Hanson, G. Boivin, and S. Chou. 1997. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J. Infect. Dis. 175:1087-1092.
75. Faizi Khan, R., S. Mori, Y. Eizuru, K. Kumura Ishii, and Y. Minamishima. 1998. Genetic analysis of a ganciclovir-resistant human cytomegalovirus mutant. Antiviral Res. 40:95-103. (Pubitemid 28535175)
76. Field, A. K., M. E. Davies, C. DeWitt, H. C. Perry, R. Liou, J. Germershausen, J. D. Karkas, W. T. Ashton, D. B. Johnston, and R. L. Tolman. 1983. 9-([2-Hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication. Proc. Natl. Acad. Sci. U. S. A. 80:4139-4143.
77. Fillet, A. M., L. Auray, S. Alain, K. Gourlain, B. M. Imbert, F. Najioullah, G. Champier, S. Gouarin, J. Carquin, N. Houhou, I. Garrigue, A. Ducancelle, D. Thouvenot, and M. C. Mazeron. 2004. Natural polymorphism of cytomegalovirus DNA polymerase lies in two nonconserved regions located between domains delta-C and II and between domains III and I. Antimicrob. Agents Chemother. 48:1865-1868.
78. Freeman, R. B., Jr. 2009. The 'indirect' effects of cytomegalovirus infection. Am. J. Transplant. 9:2453-2458.
79. Gerna, G., A. Sarasini, E. Percivalle, M. Zavattoni, F. Baldanti, and M. G. Revello. 1995. Rapid screening for resistance to ganciclovir and foscarnet of primary isolates of human cytomegalovirus from culture-positive blood samples. J. Clin. Microbiol. 33:738-741.
80. Gilbert, C., J. Bestman-Smith, and G. Boivin. 2002. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. Updat. 5:88-114.
81. Gilbert, C., and G. Boivin. 2005. Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother. 49:873-883.
82. Gilbert, C., and G. Boivin. 2005. New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure. Antimicrob. Agents Chemother. 49:4860-4866.
83. Gilbert, C., J. Handfield, E. Toma, R. Lalonde, M. G. Bergeron, and G. Boivin. 1998. Emergence and prevalence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in AIDS patients. AIDS 12:125-129. (Pubitemid 28035152)
84. Gilbert, C., J. Roy, R. Belanger, R. Delage, C. Beliveau, C. Demers, and G. Boivin. 2001. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients. Antimicrob. Agents Chemother. 45:3669-3671.
85. Gohring, K., E. Mikeler, G. Jahn, and K. Hamprecht. 2006. Rapid simultaneous detection by real-time PCR of cytomegalovirus UL97 mutations in codons 460 and 520 conferring ganciclovir resistance. J. Clin. Microbiol. 44:4541-4544.
86. Gohring, K., E. Mikeler, G. Jahn, F. Rohde, and K. Hamprecht. 2008. Rapid semiquantitative real-time PCR for the detection of human cytomegalovirus UL97 mutations conferring ganciclovir resistance. Antivir. Ther. 13:461-466.
87. Hall, J. D., K. L. Orth, K. L. Sander, B. M. Swihart, and R. A. Senese. 1995. Mutations within conserved motifs in the 3′-5′ exonuclease domain of herpes simplex virus DNA polymerase. J. Gen. Virol. 76:2999-3008.
88. Hamirally, S., J. P. Kamil, Y. M. Ndassa-Colday, A. J. Lin, W. J. Jahng, M. C. Baek, S. Noton, L. A. Silva, M. Simpson-Holley, D. M. Knipe, D. E. Golan, J. A. Marto, and D. M. Coen. 2009. Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress. PLoS Pathog. 5:e1000275.
89. Hanks, S. K., A. M. Quinn, and T. Hunter. 1988. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241:42-52.
90. Hanson, M. N., L. C. Preheim, S. Chou, C. L. Talarico, K. K. Biron, and A. Erice. 1995. Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir. Antimicrob. Agents Chemother. 39:1204-1205.
91. Hantz, S., D. Michel, A. M. Fillet, V. Guigonis, G. Champier, M. C. Mazeron, A. Bensman, F. Denis, T. Mertens, A. Dehee, and S. Alain. 2005. Early selection of a new UL97 mutant with a severe defect of ganciclovir phosphorylation after valaciclovir prophylaxis and short-term ganciclovir therapy in a renal transplant recipient. Antimicrob. Agents Chemother. 49:1580-1583.
92. He, Z., Y. S. He, Y. Kim, L. Chu, C. Ohmstede, K. K. Biron, and D. M. Coen. 1997. The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines. J. Virol. 71:405-411.
93. Hill, J. A., M. Hummel, R. C. Starling, J. A. Kobashigawa, S. V. Perrone, J. M. Arizon, S. Simonsen, K. H. Abeywickrama, and C. Bara. 2007. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 84:1436-1442.
94. Hirsch, M. S., H. F. Gunthard, J. M. Schapiro, F. Brun-Vezinet, B. Clotet, S. M. Hammer, V. A. Johnson, D. R. Kuritzkes, J. W. Mellors, D. Pillay, P. G. Yeni, D. M. Jacobsen, and D. D. Richman. 2008. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin. Infect. Dis. 47:266-285.
95. Hostetler, K. Y. 2009. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res. 82:A84-98.
96. Humar, A., D. Kumar, J. Preiksaitis, G. Boivin, D. Siegal, J. Fenton, K. Jackson, S. Nia, and D. Lien. 2005. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am. J. Transplant. 5:1462-1468.
97. Humar, A., Y. Lebranchu, F. Vincenti, E. A. Blumberg, J. D. Punch, A. P. Limaye, D. Abramowicz, A. G. Jardine, A. T. Voulgari, J. Ives, I. A. Hauser, and P. Peeters. 2010. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am. J. Transplant. 10:1228-1237.
98. Humar, A., and D. Snydman. 2009. Cytomegalovirus in solid organ transplant recipients. Am. J. Transplant. 9(Suppl. 4):S78-S86.
99. Hume, A. J., J. S. Finkel, J. P. Kamil, D. M. Coen, M. R. Culbertson, and R. F. Kalejta. 2008. Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function. Science 320:797-799.
100. Ijichi, O., D. Michel, T. Mertens, K. Miyata, and Y. Eizuru. 2002. GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E. Antiviral Res. 53:135-142. (Pubitemid 34062833)
101. Iwasenko, J. M., G. M. Scott, W. D. Rawlinson, A. Keogh, D. Mitchell, and S. Chou. 2009. Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D. J. Med. Virol. 81:507-510.
102. Jabs, D. A., C. Enger, J. P. Dunn, and M. Forman. 1998. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group. J. Infect. Dis. 177:770-773.
103. Jabs, D. A., C. Enger, M. Forman, and J. P. Dunn. 1998. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group. Antimicrob. Agents Chemother. 42:2240-2244.
104. Jabs, D. A., B. K. Martin, M. S. Forman, J. P. Dunn, J. L. Davis, D. V. Weinberg, K. K. Biron, F. Baldanti, and H. Hu. 2001. Longitudinal observations on mutations conferring ganciclovir resistance in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. The Cytomegalovirus and Viral Resistance Study Group Report Number 8. Am. J. Ophthalmol. 132:700-710.
105. Johnson, R. A., X. Wang, X. L. Ma, S. M. Huong, and E. S. Huang. 2001. Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling. J. Virol. 75:6022-6032.
106. Kamil, J. P., and D. M. Coen. 2007. Human cytomegalovirus protein kinase UL97 forms a complex with the tegument phosphoprotein pp65. J. Virol. 81:10659-10668.
107. Kedhar, S. R., and D. A. Jabs. 2007. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Herpes 14:66-71.
108. Kern, E. R., D. J. Bidanset, C. B. Hartline, Z. Yan, J. Zemlicka, and D. C. Quenelle. 2004. Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections. Antimicrob. Agents Chemother. 48:4745-4753.
109. Kern, E. R., N. L. Kushner, C. B. Hartline, S. L. Williams-Aziz, E. A. Harden, S. Zhou, J. Zemlicka, and M. N. Prichard. 2005. In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication. Antimicrob. Agents Chemother. 49:1039-1045.
110. Kimberlin, D. W., C. Y. Lin, P. J. Sanchez, G. J. Demmler, W. Dankner, M. Shelton, R. F. Jacobs, W. Vaudry, R. F. Pass, J. M. Kiell, S. J. Soong, and R. J. Whitley. 2003. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J. Pediatr. 143:16-25.
111. Komazin, G., R. G. Ptak, B. T. Emmer, L. B. Townsend, and J. C. Drach. 2003. Resistance of human cytomegalovirus to the benzimidazole L-ribo-nucleoside maribavir maps to UL27. J. Virol. 77:11499-11506.
112. Komazin, G., L. B. Townsend, and J. C. Drach. 2004. Role of a mutation in human cytomegalovirus gene UL104 in resistance to benzimidazole ribo-nucleosides. J. Virol. 78:710-715.
113. Kotton, C. N., D. Kumar, A. M. Caliendo, A. Asberg, S. Chou, D. R. Snydman, U. Allen, and A. Humar. 2010. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89:779-795.
114. Krosky, P. M., M. C. Baek, and D. M. Coen. 2003. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J. Virol. 77:905-914.
115. Krosky, P. M., M. C. Baek, W. J. Jahng, I. Barrera, R. J. Harvey, K. K. Biron, D. M. Coen, and P. B. Sethna. 2003. The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. J. Virol. 77:7720-7727.
116. Krosky, P. M., M. R. Underwood, S. R. Turk, K. W. Feng, R. K. Jain, R. G. Ptak, A. C. Westerman, K. K. Biron, L. B. Townsend, and J. C. Drach. 1998. Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J. Virol. 72:4721-4728.
117. Kudchodkar, S. B., Y. Yu, T. G. Maguire, and J. C. Alwine. 2004. Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase. J. Virol. 78:11030-11039.
118. Kuo, I. C., Y. Imai, C. Shum, D. F. Martin, B. D. Kuppermann, and T. P. Margolis. 2003. Genotypic analysis of cytomegalovirus retinitis poorly responsive to intravenous ganciclovir but responsive to the ganciclovir implant. Am. J. Ophthalmol. 135:20-25.
119. Lalezari, J. P., J. A. Aberg, L. H. Wang, M. B. Wire, R. Miner, W. Snowden, C. L. Talarico, S. Shaw, M. A. Jacobson, and W. L. Drew. 2002. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 46:2969-2976.
120. Landry, M. L., S. Stanat, K. Biron, D. Brambilla, W. Britt, J. Jokela, S. Chou, W. L. Drew, A. Erice, B. Gilliam, N. Lurain, J. Manischewitz, R. Miner, M. Nokta, P. Reichelderfer, S. Spector, A. Weinberg, B. Yen-Lieberman, and C. Crumpacker. 2000. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob. Agents Chemother. 44:688-692.
121. Lee, G. C., D. G. Lee, S. M. Choi, J. H. Yoo, S. H. Park, J. H. Choi, W. S. Min, O. H. Cho, C. H. Lee, and W. S. Shin. 2005. Use of time-saving flow cytometry for rapid determination of resistance of human cytomegalovirus to ganciclovir. J. Clin. Microbiol. 43:5003-5008.
122. Li, F., K. W. Kenyon, K. A. Kirby, D. P. Fishbein, M. Boeckh, and A. P. Limaye. 2007. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin. Infect. Dis. 45:439-447.
123. Limaye, A. P. 2002. Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients. Semin. Respir. Infect. 17:265-273.
124. Limaye, A. P. 2002. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin. Infect. Dis. 35:866-872.
125. Limaye, A. P., L. Corey, D. M. Koelle, C. L. Davis, and M. Boeckh. 2000. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356:645-649. (Pubitemid 30627592)
126. Limaye, A. P., G. Raghu, D. M. Koelle, J. Ferrenberg, M. L. Huang, and M. Boeckh. 2002. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J. Infect. Dis. 185:20-27.
127. Lischka, P., G. Hewlett, T. Wunberg, J. Baumeister, D. Paulsen, T. Goldner, H. Ruebsamen-Schaeff, and H. Zimmermann. 2010. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob. Agents Chemother. 54:1290-1297.
128. Littler, E., A. D. Stuart, and M. S. Chee. 1992. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 358:160-162.
129. Liu, S., J. D. Knafels, J. S. Chang, G. A. Waszak, E. T. Baldwin, M. R. Deibel, Jr., D. R. Thomsen, F. L. Homa, P. A. Wells, M. C. Tory, R. A. Poorman, H. Gao, X. Qiu, and A. P. Seddon. 2006. Crystal structure of the herpes simplex virus 1 DNA polymerase. J. Biol. Chem. 281:18193-18200.
130. Ljungman, P., G. L. Deliliers, U. Platzbecker, S. Matthes-Martin, A. Bacigalupo, H. Einsele, J. Ullmann, M. Musso, R. Trenschel, P. Ribaud, M. Bornhauser, S. Cesaro, B. Crooks, A. Dekker, N. Gratecos, T. Klingebiel, E. Tagliaferri, A. J. Ullmann, P. Wacker, and C. Cordonnier. 2001. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 97:388-392. (Pubitemid 32060322)
131. Loregian, A., B. A. Appleton, J. M. Hogle, and D. M. Coen. 2004. Specific residues in the connector loop of the human cytomegalovirus DNA polymerase accessory protein UL44 are crucial for interaction with the UL54 catalytic subunit. J. Virol. 78:9084-9092.
132. Lurain, N. S., S. M. Bhorade, K. J. Pursell, R. K. Avery, V. V. Yeldandi, C. M. Isada, E. S. Robert, D. J. Kohn, M. Q. Arens, E. R. Garrity, A. J. Taege, M. G. Mullen, K. M. Todd, J. W. Bremer, and B. Yen-Lieberman. 2002. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J. Infect. Dis. 186:760-768.